Today, the Medicines Control Authority of Zimbabwe announced that it has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
This follows the ,
that CAB-LA may be offered to people at substantial risk of HIV acquisition as part of comprehensive HIV prevention approaches. Two large studies showed that CAB-LA injections every 2 months were safe, well-tolerated, and highly effective in reducing
the risk of HIV acquisition and . WHO released comprehensive , calling for countries to consider this effective prevention option, and highlighted the need for implementation science to support its introduction. CAB-LA is the third PrEP product recommended by WHO for HIV prevention. Tenofovir-based oral PrEP was recommended in 2015 and the dapivirine vaginal ring, another long-acting
product, in 2021. The availability of these three products provides increased choices for HIV prevention.
Until now, CAB-LA has only received regulatory approval in 2 high-income countries. First, the for HIV prevention in December 2021. In August 2022, Australia’s Therapeutic Goods Administration (TGA) was the second national regulatory body to approve CAB-LA.
Zimbabwe is the first country in Africa and first low- and middle-income country to do so.
“WHO welcomes the news that Zimbabwe has approved the use of CAB-LA, which will pave the way for its use, providing more safe and effective options for HIV prevention,” said Dr Meg Doherty, Director of WHO’s Global HIV, Hepatitis and
Sexually Transmitted Infections Programmes.
There is considerable interest from communities in this new effective HIV prevention option.
“Accelerating HIV prevention for girls and young women requires an expansion on choices available. I am excited and proud to know that my own country Zimbabwe has approved the use of CAB-LA. This will contribute to our basket of HIV prevention tools
that work for us as girls and women in Zimbabwe,” commented Ms Nyasha Sithole, Development Agenda for Girls and Women in Africa Network (DAWA), Zimbabwe.
Regulatory approval is a crucial step in making CAB-LA available to individuals who could benefit from this new PrEP choice, and WHO will support countries to design and develop programmes so that CAB-LA can be implemented, safely and effectively, for
greatest impact. However, access to CAB-LA remains a challenge globally and making CAB-LA available at an affordable price in low- and middle-income countries is critical.
of a voluntary licensing agreement for patents relating to CAB-LA between ViiV Healthcare and the Medicine Patent Pool. WHO is working with a consortium of partners, including AVAC, Unitaid,
the Global Fund, UNAIDS and PEPFAR, to support the immediate need for delivery of CAB-LA as well as future generic production.
